Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity Clinical Trial
| Verified date | January 2010 |
| Source | Hallym University Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Korea: Food and Drug Administration |
| Study type | Interventional |
To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.
| Status | Completed |
| Enrollment | 38 |
| Est. completion date | January 2010 |
| Est. primary completion date | January 2009 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: - central macular thickness of more than 250 µm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion Exclusion Criteria: - previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset - Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders - neovascularization on the disc or elsewhere or rubeosis |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | keoung ik Na | Chuncheon | Anyang |
| Lead Sponsor | Collaborator |
|---|---|
| Hallym University Medical Center |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | best corrected visual acuity | baseline, 1 month, 2 months, 3 months, 6 months, 12 months | Yes | |
| Secondary | central macular thickness by optical coherence tomography | baseline, 1 month, 2 months, 3 months, 6 months 12months | Yes |